RecruitingPhase 3NCT06822738

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

A Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Subjects With Glaucoma


Sponsor

AbbVie

Enrollment

130 participants

Start Date

Feb 11, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab interno (inside the eye) and ab externo (outside the eye) approach. Adverse events and intraocular pressure will be assessed. XEN63 is an investigational device for the treatment of intraocular pressure (IOP) in patients with glaucoma when both medical and conventional surgical treatments have failed (for US approval) and when medical treatments have failed (for outside US \[OUS\] approval). Participants will be placed in one of two groups called study arms. One group will receive the XEN63 gel stent ab interno (inside the eye) and the other group will receive the XEN63 gel stent ab externo (outside the eye). Approximately 130 participants aged 45 years or older with glaucoma will be enrolled in this study at approximately 32 sites in the United States. Participants will receive XEN63 implanted using either the ab interno approach or the ab externo approach on Day 1 and will be followed for 12 months. Participants will attend regular visits during the study at a hospital or clinic. The safety and effect of the gel stent on your glaucoma will be checked by medical assessments and eye examinations.


Eligibility

Min Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This study evaluates the safety and effectiveness of a tiny gel implant called XEN63, which is placed inside the eye (via two different surgical approaches) to lower eye pressure in people with glaucoma that has not been adequately controlled by medications or previous eye surgery. **You may be eligible if...** - You have been diagnosed with glaucoma - Your eye pressure is not adequately controlled even with four or more classes of pressure-lowering eye drops, or fewer if some are contraindicated - You have previously had at least one unsuccessful glaucoma surgery (for the most refractory cases) - OR your eye pressure is uncontrolled on medications alone (for non-refractory cases, limited slots) **You may NOT be eligible if...** - You have had a specific type of glaucoma (such as acute angle-closure) that does not qualify - You have had recent eye surgery or infection - You have severe eye conditions that would compromise the surgery - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEXEN63 Glaucoma Treatment System

Gel Stent


Locations(21)

Arizona Advanced Eye Research Institute /ID# 268363

Glendale, Arizona, United States

LA Glaucoma Group /ID# 268444

Culver City, California, United States

North Bay Eye Associates /ID# 277071

Petaluma, California, United States

University Of Colorado - Anschutz Medical Campus /ID# 269947

Aurora, Colorado, United States

Colorado Eye Institute /ID# 277072

Colorado Springs, Colorado, United States

Brandon Eye Associates - Brandon /ID# 277074

Brandon, Florida, United States

New Vision Eye Center /ID# 269955

Vero Beach, Florida, United States

Coastal Research Associates - Roswell /ID# 268458

Roswell, Georgia, United States

Illinois Eye Center - Peoria Location /ID# 277127

Peoria, Illinois, United States

Stiles Eyecare Excellence & Glaucoma Institute /ID# 268451

Overland Park, Kansas, United States

Minnesota Eye Consultants - Minneapolis /ID# 272445

Minneapolis, Minnesota, United States

Vance Thompson Vision - Omaha /ID# 271599

Omaha, Nebraska, United States

Oklahoma Eye Surgeons /ID# 269174

Oklahoma City, Oklahoma, United States

Ophthalmic Partners of PA /ID# 276059

Bala-Cynwyd, Pennsylvania, United States

Wills Eye Hospital Glaucoma Dept /ID# 268569

Philadelphia, Pennsylvania, United States

Glaucoma Associates Of Texas /ID# 268745

Dallas, Texas, United States

UT Southwestern Medical Center /ID# 268571

Dallas, Texas, United States

El Paso Eye Surgeons /ID# 268356

El Paso, Texas, United States

Berkeley Eye Center - Houston Greenway Plaza /ID# 277078

Houston, Texas, United States

University of Virginia /ID# 277487

Charlottesville, Virginia, United States

Vistar Eye Center - Roanoke - South Jefferson Street /ID# 276119

Roanoke, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06822738


Related Trials